Venca Research
Company
Venca Research develops one asset, in phase 3 (AMO-02 in arrhythmogenic cardiomyopathy). Mostly small molecule acting on GSK3B.
- 1
- Asset
- Furthest stage
- Phase 3
- 0
- Trials
- 2
- Signals
Pipeline
1Inhibition of glycogen synthase kinase 3 beta (GSK3B).
Phase 3, Small molecule, GSK3B, arrhythmogenic cardiomyopathy, Partner
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- Signals2
- Similar companies3